Cipla stock gains momentum as brokerages bet on US recovery

Investors rally behind the pharma major after a bullish target price suggests a potential 20% upside for the stock.

The sentiment around Cipla shifted gears this week, with the cipla share price climbing 4.59% to hit Rs 1,413.90. This surge followed a vote of confidence from a foreign brokerage, which maintained a ‘Buy’ rating and set a firm target price of Rs 1,700. By placing the company on a 90-day ‘Positive Catalyst Watch,’ analysts are signaling that the firm’s period of stagnation may finally be behind it.

For a company that has navigated a challenging landscape, the optimism is tied to a series of upcoming milestones. The firm is bracing for the anticipated approval of gFlovent from its Goa manufacturing unit, alongside the planned launch of gVentolin in the United States. These moves are expected to provide much-needed momentum to its US business, which is showing signs of life after a period of weakness.

A shift in the US cycle

The narrative surrounding Cipla’s US operations has been largely defined by the decline in gRevlimid-related sales. However, the latest market analysis suggests this drag has largely played out, meaning the company’s profit cycle may have finally bottomed out. The strength of Nintedanib, which has already captured nearly half of the US market, serves as a testament to the company’s ability to compete in high-value segments.

At home, the story remains one of steady resilience. Cipla’s domestic business has found its footing again, bolstered by a clear recovery in its respiratory portfolio. As global geopolitical tensions ease, the pressure on raw material costs and margins has begun to recede, offering the company more breathing room to focus on its core growth levers.

Why it matters

This is a pivotal moment for Cipla. For shareholders, the focus now shifts to the pending re-inspection of the Indore facility. A favourable outcome with the USFDA would not just be a regulatory win—it would act as a major catalyst, clearing the path for further product approvals.

When you look at the broader market context, Cipla is being priced as a compelling entry point, trading at roughly 25 times FY27 estimated earnings. By balancing steady domestic performance with a revitalized US strategy, the company is positioning itself to capitalize on a post-revlimid reality. Whether it hits that Rs 1,700 target remains to be seen, but the current data suggests the worst of the volatility may have been priced in.